Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
← catalyst calendarSponsored by Veracyte, Inc. (industry) · VCYT — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,400estimated
Sites
23
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-18 | actual | When the study began enrolling |
| Primary completion | 2024-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pulmonary Nodule, Solitary
- Lung Cancer
Primary outcome
what the primary-completion date above is the date OFNumber of invasive diagnostic procedures
measured From date of randomization until the date the nodule is diagnosed as benign or demonstrates up to 24 months radiographic stability or resolution, assessed up to a total of 30 months.
Permalink · VCYT's whole pipeline · Catalyst calendar · Every registered study · What changed